MedTrace Logo

S-1 and Irinotecan Combination Chemotherapy for Advanced Gastric Cancer

NCT00343668 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2010-05-26

No results posted yet for this study

Summary

The primary goal of this phase II trial is to evaluate the response rate of combination chemotherapy with S-1 and Irinotecan in patients with advanced gastric cancer as a first-line therapy.

Conditions

Interventions

DRUG

S-1, irinotecan

S-1, 40 mg/m2 PO twice daily, days 1-14 irinotecan, 150 mg/m2 IV, day 1

Sponsors & Collaborators

  • Korean Cancer Study Group

    lead OTHER

Principal Investigators

  • Baek-Yeol Ryoo, M.D., Ph.D. · Korea Institute of Radiological and Medical Sciences

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Primary Completion
2007-03-31
Completion
2008-07-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00343668 on ClinicalTrials.gov